Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$5.71
+1.1%
$5.31
$1.67
$7.29
$559.52M1.012.56 million shs4.97 million shs
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
$3.72
+3.6%
$3.55
$1.78
$7.85
$160.89M3.08365,118 shs243,080 shs
Precigen, Inc. stock logo
PGEN
Precigen
$4.75
-0.2%
$2.29
$0.65
$5.23
$1.42B1.823.90 million shs9.36 million shs
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$8.61
-0.2%
$7.51
$4.95
$9.62
$616.56M0.95478,649 shs455,147 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
+5.02%+9.92%+20.21%+9.92%+202.14%
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
-3.23%-5.03%+4.36%+25.96%-55.29%
Precigen, Inc. stock logo
PGEN
Precigen
+5.54%+11.74%+185.03%+257.89%+332.73%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
+2.86%+1.65%+33.59%+40.33%-4.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
2.0115 of 5 stars
3.61.00.00.01.61.70.6
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
1.9723 of 5 stars
3.62.00.00.02.20.00.6
Precigen, Inc. stock logo
PGEN
Precigen
4.2827 of 5 stars
3.41.00.04.73.23.30.6
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
2.3535 of 5 stars
0.01.00.00.04.10.83.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.17
Buy$23.25307.18% Upside
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
3.14
Buy$16.60346.24% Upside
Precigen, Inc. stock logo
PGEN
Precigen
2.80
Moderate Buy$8.2573.68% Upside
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest KYTX, PGEN, SIGA, and ATYR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/29/2025
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.00 ➝ $10.00
8/22/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $17.00
8/20/2025
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
8/19/2025
Precigen, Inc. stock logo
PGEN
Precigen
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
8/19/2025
Precigen, Inc. stock logo
PGEN
Precigen
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00
8/19/2025
Precigen, Inc. stock logo
PGEN
Precigen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.50
8/15/2025
Precigen, Inc. stock logo
PGEN
Precigen
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral
8/13/2025
Precigen, Inc. stock logo
PGEN
Precigen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
6/20/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$17.00 ➝ $25.00
6/12/2025
Precigen, Inc. stock logo
PGEN
Precigen
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$6.00
6/4/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$230K2,432.71N/AN/A$0.76 per share7.51
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
$7.03M22.89N/AN/A$4.26 per share0.87
Precigen, Inc. stock logo
PGEN
Precigen
$3.92M361.06N/AN/A($0.12) per share-39.58
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$138.72M4.44$0.86 per share10.03$2.92 per share2.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$64.02M-$0.80N/AN/AN/AN/A-93.69%-68.83%11/6/2025 (Estimated)
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
-$127.48M-$3.68N/AN/AN/AN/A-64.98%-56.17%11/12/2025 (Estimated)
Precigen, Inc. stock logo
PGEN
Precigen
-$126.24M-$0.42N/AN/AN/A-2,868.66%-842.83%-78.98%11/13/2025 (Estimated)
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$59.21M$1.137.626.89N/A45.73%40.52%35.62%11/6/2025 (Estimated)

Latest KYTX, PGEN, SIGA, and ATYR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
-$1.00-$0.97+$0.03-$0.97N/AN/A
8/12/2025Q2 2025
Precigen, Inc. stock logo
PGEN
Precigen
-$0.14-$0.11+$0.03-$0.09$0.67 million$0.86 million
8/7/2025Q2 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.18-$0.22-$0.04-$0.22N/AN/A
8/5/2025Q2 2025
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A$0.49N/A$0.49N/A$81.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/AN/AN/AN/AN/A
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
0.01
5.63
5.63
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
N/A
5.39
5.39
Precigen, Inc. stock logo
PGEN
Precigen
N/A
2.71
2.71
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A
10.09
8.52

Institutional Ownership

CompanyInstitutional Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
61.72%
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
18.08%
Precigen, Inc. stock logo
PGEN
Precigen
33.51%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
55.40%

Insider Ownership

CompanyInsider Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.70%
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
N/A
Precigen, Inc. stock logo
PGEN
Precigen
47.10%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
1.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
5397.99 million94.36 millionOptionable
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
9643.25 millionN/AOptionable
Precigen, Inc. stock logo
PGEN
Precigen
190297.97 million157.63 millionOptionable
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
4071.61 million70.21 millionOptionable

Recent News About These Companies

Healthcare Is Sickly, But These Yields up to 7% May Still Have a Pulse
...
State of Wyoming Boosts Stake in Siga Technologies Inc. $SIGA
SIGA (SIGA) Q2 Revenue Soars 272%

New MarketBeat Followers Over Time

Media Sentiment Over Time

aTyr Pharma stock logo

aTyr Pharma NASDAQ:ATYR

$5.71 +0.06 (+1.06%)
Closing price 04:00 PM Eastern
Extended Trading
$5.69 -0.02 (-0.35%)
As of 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Kyverna Therapeutics stock logo

Kyverna Therapeutics NASDAQ:KYTX

$3.72 +0.13 (+3.62%)
Closing price 04:00 PM Eastern
Extended Trading
$3.72 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Precigen stock logo

Precigen NASDAQ:PGEN

$4.75 -0.01 (-0.21%)
Closing price 04:00 PM Eastern
Extended Trading
$4.78 +0.03 (+0.53%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Siga Technologies stock logo

Siga Technologies NASDAQ:SIGA

$8.61 -0.02 (-0.23%)
Closing price 04:00 PM Eastern
Extended Trading
$8.50 -0.11 (-1.29%)
As of 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.